Ex vivo serum activity (killing rates) after gemifloxacin 320 mg versus trovafloxacin 200 mg single doses against ciprofloxacin-susceptible and -resistant Streptococcus pneumoniae [1]

  1. Calvo, A.
  2. Giménez, M.J.
  3. Alou, L.
  4. Gómez-Lus, M.L.
  5. Aguilar, L.
  6. Prieto, J.
Journal:
International Journal of Antimicrobial Agents

ISSN: 0924-8579

Year of publication: 2002

Volume: 20

Issue: 2

Pages: 144-146

Type: Letter

DOI: 10.1016/S0924-8579(02)00119-X GOOGLE SCHOLAR

Sustainable development goals

Data source: Scopus